Patisiran

帕替司兰

Report date: 2026/04/21 20:00:18
NMEFirst In Class

Base Information

Drug NamePatisiran
Drug Alias Namepatisiran sodiumpatisiran-LNPOnpattroSAR-438037GENZ-438027 +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceTransthyretin inhibitors
TargetsTransthyretin
Therapy Area/IndicationsTransthyretin amyloidosisAmyloidosisAmyloidosis, Familial +[7] 
Global Approved IndicationsTransthyretin amyloidosisAmyloidosis, FamilialAmyloid Neuropathies, Familial
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/08/10
Country/TerritoryCzechiaBelgiumBulgaria +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofiAlnylam Netherlands BvAlnylam Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsTransthyretin amyloidosisAmyloidosisAmyloidosis, Familial +[6] 
Inactive IndicationsAmyloid Neuropathies

Other Information

ATC CodeN07XX12
Related LinksWikipediaDrugBankKEGG